Torisel Articles
Pfizer says Torisel combo fails in Ph III for kidney cancer
13 August 2012
Negative decisions from UK’s NICE for Novartis’ Xolair, GSK’s Arzerra and Pfizer’s Torisel, but OK for Amgen’s Prolia
27 October 2010
Changes predicted in renal cell carcinoma market leaders
15 September 2009
"Perverse" NICE again says "No" to new drugs
28 April 2009
Sutent cleared for UK kidney cancer patients
30 March 2009
Sutent available in England, not Scotland
9 February 2009
Wyeth welcomes NICE review of Torisel
10 November 2008
US and UK Prix Galien awards 2008, winners announced
6 October 2008
Pfizer economic study says Sutent cost effective in mRCC
22 September 2008
UK cancer charity slams NICE methods
11 August 2008
Everolimus trial halted after early PFS gains
10 March 2008
EC approves Wyeth's Torisel in advanced RCC
3 December 2007
Wyeth sets sights on Japanese market
15 October 2007
Toricel gets CHMP nod as first-line RCC drug
1 October 2007
Wyeth's 2nd-qtr net income climbs 12.5%
30 July 2007
FDA extends review on Wyeth's first-in-class mTOR inhibitor, Torisel, in advanced renal cell carcinoma
16 April 2007
FDA priority review for Wyeth's Torisel
22 December 2006
Wyeth's income climbs 33% to $1.16B in 3rd-qtr, on continued success of Enbrel and Prevnar
30 October 2006
Wyeth unveils seven late-stage drugs for 11 indications at its annual R&D presentation
16 October 2006
Wyeth's revenues hit $5.2B for 1st-half 2006
31 July 2006
Showing 1-26 of 26 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
